Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 9, 2010, Pages 2983-2986

  Yan, Yinfa ^a   Zhou, Ping ^a   Rotella, David P ^a   Feenstra, Rolf ^b   Kruse, Chris G ^b   Reinders, Jan Hendrik ^b   Neut, Martina van der ^b   Lai, Margaret ^a   Zhang, Jean ^a   Kowal, Dianne M ^a   Carrick, Tikva ^a   Marquis, Karen L ^a   Pausch, Mark H ^a   Robichaud, Albert J ^a  

^a PFIZER INC   (United States)

^b Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

Dopamine D2 partial agonist; Schizophrenia; Serotonin reuptake inhibitor

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

AMINATION; ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG SYNTHESIS; HORNER REACTION; IN VITRO STUDY; PHARMACOPHORE; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; QUINOLONES; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77950859625     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.02.105     Document Type: Article

References (13)

1. Tohen M., Vieta E., Calabrese J., Ketter T.A., Sachs G., Bowden C., Mitchell P.B., Centorrino F., Risser R., Baker R.W., Evans A.R., Beymer K., Dube S., Tollefson G.D., and Breier A. Arch. Gen. Psychiatry 60 (2003) 1079
2. Amsterdam J.D., and Shults J. J. Affect. Disord. 87 (2005) 121
3. Benazzi F., Berk M., Frye M.A., Wang W., Barraco A., and Tohen M. J. Clin. Psychiatry 70 (2009) 1424
4. Rotella D.P., McFarlane G.R., Greenfield A., Grosanu C., Robichaud A.J., Feenstra R.W., Núñez-Garcia S., Reinders J.-H., van der Neut M., McCreary A., Kruse C.G., Sullivan K., Pruthi F., Lai M., Zhang J., Kowal D.M., Carrick T., Grauer S.M., Navarra R.L., Graf R., Brennan J., Marquis K.L., and Pausch M.H. Bioorg. Med. Chem. Lett. 19 (2009) 5552
5. Chris L.B., and Bruce M.P. Curr. Control Trials Cardiovasc. Med. 3 (2002) 7
6. Melzer H.Y. Neuropsychopharmacology 21 (1999) 106S
7. McGavin J.K., and Goa K.L. CNS Drugs 16 (2002) 779
8. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., and Mailman R. Neuropsychopharmacology 28 (2003) 1400
9. Stack, G. P. US 5,869,490, 1999.
10. Galante, R. J. WO2007139998, 2007.
11. Failli, A. A.; Evrard, D.; Li, Y.; Hatzenbuhler, N. T.; Mogish, J.; Gunawan, I. S.; Nikitenko, A.; Zhou, P., US20070530, 2008.
12. Compound 19 see Ref. 9; compounds 20 and 21:. Mewshaw R.E., Husbands M., Gildersleeve E.S., Webb M.B., Shi X., Mazandarani H., Cockett M.I., Ochalski R., Brennan J.A., Abou-Gharbia M., Marquis K., McGaughey G.B., Coupet J., and Andree T.H. Bioorg. Med. Chem. Lett. 8 (1998) 295
13. All target compounds were characterized by NMR, analytical HPLC and MS, and were at least 97% pure.